Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2009; 30(03): 113-115
DOI: 10.4103/0971-5851.64258
CASE REPORT

Uterine C-Kit positive low grade stromal sarcoma

Jovitha Martin
Department of Oncology, Sri Ramachandra Medical College, Chennai, India
,
Anita Ramesh
Department of Oncology, Sri Ramachandra Medical College, Chennai, India
,
Sarah Kuruvilla
Department of Pathology, Sri Ramachandra Medical College, Chennai, India
,
D Lalitha
Department of Obstetrics and Gynecology, Sri Ramachandra Medical College, Chennai, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Uterine C-Kit positive stromal tumors are rare, however, there are a few cases reported in literature. A 58-year-old post menopausal lady presented with bleeding per vaginum. An abdominal examination revealed an enlarged uterus. A computed tomography scan of the abdomen and pelvis showed a large myomatous uterus, with a probable subserosal intramural and intracavitary myoma or cervical myoma in the presence of a solitary large aortocaval node, with multiple bone lesions. The biopsy taken from the uterine mass had revealed, a low-grade uterine sarcoma, which was positive for CD117. This case is presented for its rarity and management dilemma.

Keywords

C-Kit - stromal sarcomas - uterine


Publication History

Article published online:
19 November 2021

© 2009. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Leung F, Terzibachian JJ, Gay C, Chung Fat B, Aouar Z, Lassabe C, et al. Hysterectomies performed for presumed leiomyomas: Should the fear of leiomyosarcoma make us apprehend non laparotomic surgical routes? Gynecol Obstet Fertil 2009;37:109-14.
  • 2 Kalender ME, Sevinc A, Yilmaz M, Ozsarac C, Camci C. Detection of complete response to imatinib mesylate [Glivec/Gleevec] with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother Pharmacol 2009;63:555-9.
  • 3 Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982;5:649-55.
  • 4 Chow E, Hoskin P, van der Linden Y, Bottomley A, Velikova G. Quality of life and symptom end points in palliative bone metastases trials. Clin Oncol [R Coll Radiol] 2006;18:67-9.
  • 5 Raspollini MR, Amunni G, Villanucci A, Pinzani P, Simi L, Paglierani M, et al. c-Kit expression in patients with uterine leiomyosarcomas: A potential alternative therapeutic treatment. Clin Cancer Res 2004;10:3500-3.
  • 6 Nakayama M, Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Ishihara O, et al. Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region. Int J Gynecol Pathol 2006;25:70-6.
  • 7 Caudell JJ, Deavers MT, Slomovitz BM, Lu KH, Broaddus RR, Gershenson DM, et al. Imatinib mesylate [gleevec]--targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol 2005;13:167-70.
  • 8 Leath CA 3rd, Straughn JM Jr, Conner MG, Barnes MN 3rd, Alvarez RD, Partridge EE, et al. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: A case series J Reprod Med 2004;49:71-5.
  • 9 Wang L, Felix JC, Lee JL, Tan PY, Tourgeman DE, O′Meara AT, et al. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Oncol 2003;90:402-6.
  • 10 Menczer J, Kravtsov V, Levy T, Berger E, Glezerman M, Avinoach I. Expression of c-kit in uterine carcinosarcoma. Gynecol Oncol 2005;96:210-5.